Does ENZALUTAMIDE Cause Therapy cessation? 45 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 45 reports of Therapy cessation have been filed in association with ENZALUTAMIDE (Xtandi). This represents 0.1% of all adverse event reports for ENZALUTAMIDE.
45
Reports of Therapy cessation with ENZALUTAMIDE
0.1%
of all ENZALUTAMIDE reports
6
Deaths
10
Hospitalizations
How Dangerous Is Therapy cessation From ENZALUTAMIDE?
Of the 45 reports, 6 (13.3%) resulted in death, 10 (22.2%) required hospitalization, and 2 (4.4%) were considered life-threatening.
Is Therapy cessation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENZALUTAMIDE. However, 45 reports have been filed with the FAERS database.
What Other Side Effects Does ENZALUTAMIDE Cause?
Fatigue (8,891)
Death (6,680)
Malignant neoplasm progression (4,696)
Prostatic specific antigen increased (3,731)
Asthenia (3,589)
Drug ineffective (3,468)
Hot flush (3,144)
Decreased appetite (3,069)
Nausea (2,898)
Dizziness (2,776)
What Other Drugs Cause Therapy cessation?
DALFAMPRIDINE (4,580)
ETANERCEPT (2,031)
ADALIMUMAB (1,712)
ABIRATERONE (1,602)
VOXELOTOR (1,038)
CLOZAPINE (885)
LOMITAPIDE (828)
CAPECITABINE (746)
TREPROSTINIL (743)
ISOTRETINOIN (633)
Which ENZALUTAMIDE Alternatives Have Lower Therapy cessation Risk?
ENZALUTAMIDE vs EPCORITAMAB
ENZALUTAMIDE vs EPCORITAMAB-BYSP
ENZALUTAMIDE vs EPERISONE
ENZALUTAMIDE vs EPHEDRINE
ENZALUTAMIDE vs EPINASTINE